Yamamoto, Noboru http://orcid.org/0000-0002-0787-2851
Shimizu, Toshio
Yonemori, Kan
Kitano, Shigehisa
Kondo, Shunsuke
Iwasa, Satoru
Koyama, Takafumi
Sudo, Kazuki
Sato, Jun
Tamura, Kenji
Tomomatsu, Junichi
Ono, Makiko
Fukuda, Naoki
Takahashi, Shunji
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 17 November 2020
Accepted: 16 December 2020
First Online: 9 February 2021
Compliance with ethical standards
:
: Noboru Yamamoto reports grants from Chugai, Taiho, Eisai, Eli Lilly, Quintiles, Astellas, Bristol-Myers Squibb, Novartis, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, Kyowa Hakko Kirin, Bayer, Ono, Takeda, GlaxoSmithKline, Sumitomo Dainippon Pharma, Chiome Bioscience Inc., Janssen, MSD, and Merck; and personal fees from Ono, Chugai, AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Eisai, Otsuka, Takeda, Boehringer Ingelheim, Cimic, and Sysmex, outside the submitted work.Toshio Shimizu reports grants from Novartis, Eli Lilly, Daiichi-Sankyo, Bristol-Myers Squibb, Eisai, AbbVie, AstraZeneca, Takeda Oncology, Incyte, Pfizer, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, Five Prime, and Astellas; and personal fees from Taiho, Boehringer Ingelheim, Chugai, Ono, Takeda, and AbbVie, outside the submitted work.Kan Yonemori reports personal fees from Ono, Pfizer, Takeda, Eisai, Novartis, AstraZeneca, and Chugai, outside the submitted work.Shigehisa Kitano reports personal fees from Nippon Kayaku, Meiji Seika Pharma, Taiho, Novartis, Daiichi-Sankyo, MSD, Kyowa Hakko Kirin, Celgene, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, AYUMI Pharmaceutical Corporation, Rakuten Medical, PMDA (Pharmaceuticals and Medical Devices Agency), and GSK; grants and personal fees from Boehringer Ingelheim, Eisai, Ono, and REGENERON; and grants from Astellas, Gilead Sciences, AMED (Japan Agency for Medical Research and Development), and JSPS (Japan Society for the Promotion of Science), outside the submitted work.Shunsuke Kondo has received research funding from ASLAN Pharmaceuticals, Eisai, AstraZeneca, Bayer, Eli Lilly, MSD, and Pfizer.Satoru Iwasa reports personal fees from Taiho, Merck-Serono, Eli Lilly, and Chugai; grants and personal fees from Ono; and grants from Daiichi-Sankyo, Bristol-Myers Squibb, Bayer, and Astellas, outside the submitted work.Takafumi Koyama reports honoraria from Cysmex and Chugai, outside the submitted work.Jun Sato reports personal fees from Chugai, during the conduct of the study.Junichi Tomomatsu reports personal fees from Eisai, during the conduct of the study.Naoki Fukuda reports personal fees from Eisai, outside the submitted work.Shunji Takahashi reports grants and personal fees from Taiho, during the conduct of the study; and grants and personal fees from MSD, AstraZeneca, Chugai, Ono, Bristol-Myers Squibb, and Eisai, and grants from Novartis, outside the submitted work.Kazuki Sudo, Kenji Tamura, and Makiko Ono have nothing to disclose.
: The study was reviewed and approved by the institutional review board at each study site. The study was conducted in compliance with the guidelines provided in the Declaration of Helsinki, Good Clinical Practice, and all applicable local and national regulations.
: All patients provided written informed consent prior to study participation.
: Not applicable.
: Not applicable.